Duke specialists to detail the benefits of treating heart failure with Barostim

Heart failure rates are on the rise, a trend that is only expected to get worse and worse in the years ahead. Cardiologists, meanwhile, are working to fight back through the use of new treatment techniques and technologies. 

Duke University Health System, for instance, has integrated the implantable Barostim device from CVRx into its nationally recognized heart failure program. Barostim is designed to help patients with heart failure and a low or reduced ejection fraction by sending small electrical pulses to certain sensors in the neck, which then communicate with the brain to regulate the heart, kidneys and vascular system. 

This communication typically occurs without any sort of therapy, but it happens less frequently in heart failure patients, creating significant health risks.

Barostim Neo 2 CVRx heart failure nerve stimulator on display at HRS 2023. Photo by Dave Fornell

What, exactly, made Barostim such a good fit for Duke? How did integrating the implantable device impact patient care? Those are just some of the questions that will be discussed during an upcoming webinar and live Q&A session co-sponsored by Cardiovascular Business and CVRx.

The webinar’s expert panel is scheduled to include three guests:

  • Marat Fudim, MD, MHS, a cardiologist and medical director of the device clinic at Duke University Health System
  • Joanna Kipnes, MD, MS, FHM, a hospital medicine specialist and medical director of utilization management at Duke University Health System a well as the associate chief medical officer of Duke’s Patient Revenue Management Organization
  • Bonnie Handke, RN, MBA, senior vice president of patient access, reimbursement and healthcare economics at CVRx.

The group is expected to touch on a wide variety of topics, including everything from the actual technology to what providers need to know about the billing and reimbursement sides of things. The material should interest cardiologists, advance heart failure specialists, administrators, reimbursement specialists, cardiovascular service line directors, surgeons, hospital and health system executives and anyone looking to improve care for heart failure patients.

The free webinar is scheduled for Thursday, May 22, at 1 p.m. ET. Click here for more information, including registration details. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.